{"nctId":"NCT01497366","briefTitle":"Phase 3 Study of Sofosbuvir and Ribavirin","startDateStruct":{"date":"2011-12"},"conditions":["Hepatitis C"],"count":527,"armGroups":[{"label":"Sofosbuvir+RBV","type":"EXPERIMENTAL","interventionNames":["Drug: Sofosbuvir","Drug: RBV"]},{"label":"PEG+RBV","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: PEG","Drug: RBV"]}],"interventions":[{"name":"Sofosbuvir","otherNames":["Sovaldi™","GS-7977","PSI-7977"]},{"name":"PEG","otherNames":["Pegasys®"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic Genotype 2 or 3 HCV-infection\n* Naive to all HCV antiviral treatment(s)\n\nExclusion Criteria:\n\n* Positive test at Screening for HBsAg, anti-hepatitis B core immunoglobulin M antibody (anti-HBc IgM Ab), or anti-HIV Ab\n* History of any other clinically significant chronic liver disease\n* A history consistent with decompensated liver disease\n* History or current evidence of psychiatric illness, immunologic disorder, hemoglobinopathy, pulmonary or cardiac disease, seizure disorder or anticonvulsant use, poorly controlled diabetes, cancer, or a history of malignancy, that makes the subject unsuitable for the study.\n* Participation in a clinical study within 3 months prior to first dose","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Stopping All Study Drugs (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; \\< 25 IU/mL) 12 weeks after study drug cessation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 24 Weeks After Stopping All Study Drugs (SVR24)","description":"SVR24 was defined as HCV RNA \\< LLOQ 24 weeks after study drug cessation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.8","spread":null},{"groupId":"OG001","value":"65.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ on Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null},{"groupId":"OG001","value":"31.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"66.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.26","spread":"0.689"},{"groupId":"OG001","value":"-2.19","spread":"1.287"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.60","spread":"0.820"},{"groupId":"OG001","value":"-3.19","spread":"1.572"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.64","spread":"0.816"},{"groupId":"OG001","value":"-4.04","spread":"1.389"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.63","spread":"0.850"},{"groupId":"OG001","value":"-4.42","spread":"1.163"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.65","spread":"0.820"},{"groupId":"OG001","value":"-4.45","spread":"1.226"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure During Treatment","description":"Virologic failure was defined as either\n\n* Viral breakthrough: HCV RNA ≥ 25 IU/mL after having previously had HCV RNA \\< 25 IU/mL while on treatment, confirmed with 2 consecutive values or last available measurement\n* Viral rebound: \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values or last available measurement\n* Non-response: HCV RNA persistently ≥ 25 IU/ml while on treatment (through Week 12)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Relapse Following Treatment","description":"Viral relapse was defined as HCV RNA ≥ 25 IU/mL in post-treatment after having achieved \\< LLOQ at last on-treatment measurement, confirmed with 2 consecutive values or last available measurement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":null},{"groupId":"OG001","value":"22.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":256},"commonTop":["Fatigue","Headache","Nausea","Insomnia","Rash"]}}}